18F-FDG PET Metabolic Phenotype in Evaluating Therapeutic Response for Breast Cancer Patients With Bone Metastases.
18F-FDG PET Metabolic Phenotype in Evaluating Therapeutic Response for Breast Cancer Patients With Bone Metastases.
This study is to evaluate the effectiveness of 18F-FDG PET in following up of metastastic
 bone lesions and in predicting outcome for breast cancer patients after therapy.

 Primary outcome: Using 18F-FDG uptake to evaluate the metastatic bone status after treatment.
 The PET results will be compared with the results in Tc-99m MDP bone scintigraphy.

 Secondary outcome: Evaluate the relationship between the 18F-FDG uptake of the metastatic
 bone lesions and (1) breast cancer related tumor marker, (2) patients' survival.
Background: Although 99mTc MDP bone scintigraphy is a sensitive tool for screening metastatic
 bone status, it is not a satisfactory imaging modality in evaluating residual disease after
 therapy. 18F-FDG PET has been an effective imaging tool for many malignancies including
 breast cancer, not only in diagnosis and staging, but also in monitoring response and
 following up disease status after therapy.

 Purpose: This study is to evaluate the effectiveness of 18F-FDG PET in following up of
 metastastic bone lesions and in predicting outcome for breast cancer patients after therapy.

 Method: Breast cancer patients with bone metastases, age 20-90 year-old, will be included in
 this study.

 Primary outcome: Using 18F-FDG uptake to evaluate the metastatic bone status after treatment.
 The PET results will be compared with the results in Tc-99m MDP bone scintigraphy.

 Secondary outcome: Evaluate the relationship between the 18F-FDG uptake of the metastatic
 bone lesions and (1) breast cancer related tumor marker, (2) patients' survival.
Inclusion Criteria:

 1. Age：20-90 years old

 2. Histological proven breast cancer, with known metastatic bone lesion(s)

 3. written informed consent signed

 Exclusion Criteria:

 1. pregnant or intend to be pregnant

 2. other malignancies known